Business Context and Reporting Period
This Form 8-K was filed by Onconova Therapeutics, Inc. on February 5, 2018, reporting events occurring on February 2, 2018. The Company is an emerging growth company incorporated in Delaware. The filing addresses the Company's status regarding its listing on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or margin data. It specifically references historical stockholders' equity figures to explain the listing non-compliance:
- March 31, 2017: $(2.7) million
- June 30, 2017: $0.4 million
- September 30, 2017: $(6.1) million
The Company failed to meet the Nasdaq minimum stockholders' equity requirement of $2.5 million.
Material Changes
The primary material change is the outcome of a hearing before the Nasdaq Hearings Panel. On February 2, 2018, the Panel granted the Company an extension until April 13, 2018, to regain compliance with Nasdaq listing requirements. This decision follows previous notifications of non-compliance and a hearing held on January 18, 2018.
Outlook, Risks, and Contingencies
To regain compliance by the April 13, 2018 deadline, the Company must demonstrate either:
- Minimum stockholders' equity of $2.5 million; or
- A market value of listed securities of at least $35 million for ten consecutive trading days.
Management states there is no assurance that compliance will be regained or maintained. Risks associated with potential delisting include:
- Difficulty in buying or selling securities and obtaining accurate quotations.
- A material decline in the price of securities.
- Impaired ability to raise capital.
Investor Verification Checklist
- Verify the Company's current stockholders' equity and market capitalization to assess the feasibility of meeting the April 13, 2018 deadline.
- Monitor subsequent filings for updates on the Company's plan to regain compliance.
- Review the Company's liquidity position given the stated risk of impaired capital raising ability if delisted.
- Confirm the trading status of the stock on The Nasdaq Capital Market.